Find Reports
Select Report Type
Reimbursement Review
Displaying 626 - 650 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Sapropterin dihydrochloride | Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | SR0472-000 | |||
| lumacaftor/ivacaftor | Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation | Do not reimburse | Complete | SR0471-000 | |||
| Infliximab | Inflectra (Subsequent Entry Biologic) | Infliximab | Crohn’s disease and Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | SE0483-000 | |||
| Etanercept | Brenzys | Etanercept | Rheumatoid arthritis, Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | SE0485-000 | |||
| Ixekizumab | Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0481-000 | |||
| Empagliflozin and metformin | Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | SR0489-000 | |||
| Lynparza for Ovarian Cancer (2... | Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | PC0081-000 | |||
| Zydelig for Follicular Lymphom... | Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | PC0075-000 | |||
| Lenvima for Differentiated Thy... | Lenvima | Lenvatinib | Differentiated Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0080-000 | |||
| Opdivo for Metastatic Renal Ce... | Opdivo | Nivolumab | Metastatic Renal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0074-000 | |||
| Canagliflozin and metformin hy... | Invokamet | Canagliflozin and metformin hydrochloride | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0480-000 | |||
| ticagrelor | Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | SR0474-000 | |||
| Tesamorelin | Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | SR0477-000 | |||
| Emtricitabine/tenofovir disopr... | Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | SR0479-000 | |||
| Emtricitabine /tenofovir alafe... | Descovy | Emtricitabine /tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0470-000 | |||
| Secukinumab | Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | SR0475-000 | |||
| Secukinumab | Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | SR0476-000 | |||
| Yondelis for Liposarcoma or Le... | Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | PC0071-000 | |||
| Aflibercept | Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | SR0460-000 | |||
| teduglutide | Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | SR0459-000 | |||
| Asunaprevir | Sunvepra | Asunaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | SR0418-000 | |||
| dapagliflozin/metformin hydroc... | XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | SR0468-000 | |||
| Alirocumab | Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | SR0469-000 | |||
| Imbruvica for Mantle Cell Lymp... | Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Complete | PC0073-000 | |||
| Cotellic for Metastatic Melano... | Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0070-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 626 - 650 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Hearing Aids and Dementia | Horizon Scan | Emerging Health Technologies | Completed | EH0120-000 | |||
| Rapid HIV Self-Testing | Horizon Scan | Emerging Health Technologies | Completed | EH0118-000 | |||
| Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies | Health Technology Review | Rapid Review | Completed | RC1484-000 | |||
| Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0030-000 | |||
| Antimicrobial or Antiseptic Cleansers for Wounds | Health Technology Review | Rapid Review | Completed | RC1488-000 | |||
| mavacamten | Reimbursement Review | Complete | SR0755-000 | ||||
| CADTH Pharmaceutical Reviews Update — Issue 39 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Triple Negative Breast Cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0024-000 | |||
| Deep Brain Stimulation Surgery Programs in Canada | Health Technology Review | Technology Review | Completed | HC0065-000 | |||
| Hybrid Operating Rooms Suites | Horizon Scan | Emerging Health Technologies | Completed | EH0121-000 | |||
| axicabtagene ciloleucel | Reimbursement Review | Complete | PG0293-000 | ||||
| CADTH Pharmaceutical Reviews Update — Issue 38 | Reimbursement Review | Pharmaceutical Review Update | |||||
| ravulizumab | Reimbursement Review | Complete | SR0740-000 | ||||
| An Overview of Pharmacogenomic Testing for Psychiatric Disorders | Horizon Scan | Emerging Health Technologies | Completed | EH0115-000 | |||
| Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0028-000 | |||
| RET fusion-positive non-small cell lung cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0026-000 | |||
| Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases | Health Technology Review | Summary with Critical Appraisal | Completed | RC1483-000 | |||
| CADTH Pharmaceutical Reviews Update — Issue 37 | Reimbursement Review | Pharmaceutical Review Update | |||||
| cemiplimab | Reimbursement Review | Complete | PC0260-000 | ||||
| finerenone | Reimbursement Review | Complete | SR0737-000 | ||||
| Chloroprocaine for Spinal or Epidural Anesthesia | Health Technology Review | Rapid Review | Completed | RC1482-000 | |||
| pegcetacoplan | Reimbursement Review | Complete | SR0748-000 | ||||
| Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer | Health Technology Review | Rapid Review | Completed | RC1481-000 | |||
| Overview of HTA Processes for Time-limited Recommendations | Health Technology Review | Environmental Scan | Completed | ES0377-000 | |||
| Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome | Health Technology Review | Rapid Review | Completed | RC1480-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81